As of February 1, 2017 state laws disparately regulate patient registration and civil rights, product safety labeling and packaging, and dispensaries, creating a patchwork of regulatory strategies whose effectiveness remains unknown.
Aaron Kesselheim, MD, JD, MPH, of the Division of Pharmacoepidemiology & Pharmacoeconomics at Brigham and Women’s Hospital discusses the effects on medical innovation of statutes that provide additional intellectual property rights or related incentives to pharmaceutical, medical device, and biotechnology developers in the U.S.
